Health Care Provider Perspectives on Once-Daily Extended-Release Ruxolitinib Among Ruxolitinib-Eligible Patients With Myelofibrosis, Polycythemia Vera, and Graft-vs-Host Disease (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1097; "Once-daily ruxolitinib XR was viewed as a meaningful dosing advancement that might support adherence and treatment continuity in specific patient populations, particularly those at risk of nonadherence, when comparable efficacy, safety, and dosing flexibility are maintained. GVHD: graft-vs-host disease, NCCN: National Comprehensive Cancer Network, PV: polycythemia vera."
Clinical • Myelofibrosis • Oncology • Polycythemia Vera
|
|
Verma Sumit BPharm,MS 1; Jesse Cohn PhD 2; Bhavna Murali PhD 2; Elizabeth McCaig 2; Shreekant Parasuraman PhD 1
|